GlassScriptPhysician profile
Karen Feghali
NPI 1740832427
$479.07
in general payments reported to CMS, 2019-2025
16 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $243 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $479.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $100.05 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $44.44 | 2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $42.13 | 2024-2025 | Zepbound, Mounjaro |
| Beta Bionics, INC. | $39.35 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Emd Serono, INC. | $34.88 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.66 | 2025 | Jardiance |
| Tandem Diabetes Care, INC. | $25.40 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $22.28 | 2024 | Minimed 780g |
| Insulet Corporation | $21.91 | 2025 | Omnipod |
| Corcept Therapeutics | $19.69 | 2024 | Korlym |
| Xeris Pharmaceuticals, INC. | $19.17 | 2025 | Gvoke Hypopen |
| Beigene USA, INC. | $18.20 | 2024 | Brukinsa |
| Eisai INC. | $17.08 | 2024 | |
| Puma Biotechnology, INC. | $14.98 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.66 | 2024 | Hyqvia |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $13.19 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Feghali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.